Hepatic fibrosis and its end-stage sequelae of cirrhosis and liver cancer are major causes of morbidity and mortality throughout the world and their prevalence is rising, largely due to the increasing impact of chronic viral hepatitis and nonalcoholic steatohepatitis (NASH). Therapies currently available are only to manage patients suffering from or progressing to liver cirrhosis. In Western medicine the lack of treatments to target the arrest or reverse the progression of disease hampered the clinicians to successfully treat these patients with established cirrhosis. This review focused on the Hepatic fibrosis and importance herbal medicines for prevention and treatment of chronic liver diseases. © 2015 M.P.B. Wijayagunawardane, C.U.B. Wijerathne, C.B. Herath. Published by Elsevier B.V. Peer-review under responsibility of the Scientific Committee of HK-ICONS 2014.
Introduction
The use of medicinal plants for treatment of various diseases has been practiced for centuries in the Asian continent. It is thought that indigenous medical practice of Sri Lanka was introduced from India long ago. However, historical evidence indicates that a traditional system of veterinary medicine existed even 5 000 years ago during the time of King Rawana. The Indian ayurvedic system came to Sri Lanka, especially with the advent of Buddhism around 2600 years ago, where a group of "Ayurvedic" specialists accompanied "MahindaThero" when he came to "Mihintale". On the other hand, Siddha system of medicine came to Sri Lanka with the Hindu Tamil migrants and Uani system came with the Muslim merchants who came to Sri Lanka. Thus, indigenous medical practices of Sri Lanka became a mixture of all these systems, but still the traditional system of medicine is being practiced 1 .Thepress practice of indigenous medicine in Sri Lanka was reaching the peak during 337 to 365 A. D. at the time of king "Buddadasa" 2 . However, with the invasion of the western power the practice of indigenous medicine was gradually declined but is still being practiced in isolated pockets in remote areas of the country In the monographs of indigenous medical practices valuable information on diagnosis, rationales of the treatment with prognosis are described for various diseases, including respiratory, uro-genital, nervous, musculoskeletal, gastro-intestinal disorders as well as external disease conditions such as wounds, broken bones/horns, skin diseases 3 . According to the indigenous medical practice, a part or whole of a single plant or mixture of various parts of plants including flowers, rhizomes, stems, fruits, roots, tubers, leaves, stem-barks, seeds are used to make various herbal preparations including decoctions, juices, powders, oil extracts. The unique feature in indigenous veterinary medicine is that, for the same disorder the type and part of plants and their proportions used can be vary with the locality/region or with the practitioner [3] [4] [5] . The herbal recipes are usually combined with tattooing and do inchantation (a formula of prayer addressed to a deity or devil).
Hepatic Fibrosis and Historical Perspective
Hepatic fibrosis and its end-stage sequelae of cirrhosis and liver cancer are major causes of morbidity and mortality throughout the world and their prevalence is rising, largely due to the increasing impact of chronic viral hepatitis and non-alcoholic steatohepatitis (NASH). It is hoped better disease prevention and more effective antiviral therapies will help reduce this disease burden. However, there remains a major need both to understand the mechanisms involved in hepatic fibrosis in order to design treatments that prevent liver scarring, and to develop better therapies for the treatment of cirrhosis and its complications.
Liver fibrosis results from chronic damage to the liver in conjunction with the accumulation of extra cellular matrix (ECM) proteins, which is a characteristic of most types of chronic liver diseases 6 . The main causes of liver fibrosis include chronic HCV infection, alcohol abuse, and nonalcoholic steatohepatitis (NASH). The accumulation of ECM proteins distorts the hepatic architecture by forming a fibrous scar, and the subsequent development of nodules of regenerating hepatocytes defines cirrhosis. Cirrhosis produces hepatocellular dysfunction and increased intrahepatic resistance to blood flow, which result in hepatic insufficiency and portal hypertension, respectively 7 . Hepatic fibrosis was historically thought to be a passive and irreversible process due to the collapse of the hepatic parenchyma and its substitution with a collagen-rich tissue 8 .
Currently, it is considered a model of the wound-healing response to chronic liver injury. Early clinical reports in the 1970s suggested that advanced liver fibrosis is potentially reversible 9 . However, liver fibrosis received little attention until the 1980s, when hepatic stellate cells (HSCs), formerly known as lipocytes, Ito cells, or perisinusoidal cells, were identified as the main collagen-producing cells in the liver 10 . This cell type undergoes a dramatic phenotypic activation in chronic liver diseases with the acquisition of fibrogenic properties 11 . Methods to obtain HSCs from both rodent and human livers were rapidly standardized in the 1980s 12 and prolonged culture of HSCs on plastic was widely accepted as a model for the study of activated HSCs and the key signals that modulate HSCs' fibrogenic actions were delineated 13 . Experimental models for studying liver fibrogenesis in rats and in transgenic mice were developed, which corroborated the cell culture studies and led to the identification of key fibrogenic mediators 14 .
At the clinical level, the natural history of liver fibrosis, from early changes to liver cirrhosis, was delineated in patients with chronic HCV infection 15 . Rapid and slower fibrosers were identified, and genetic and environmental factors influencing fibrosis progression were partially uncovered. Since the demonstration, in the 1990s, that even advanced liver fibrosis is reversible,researchers have been stimulated to identify antifibrotic therapies 16 . Biotechnology and pharmaceutical companies are increasingly interested in developing antifibrotic programs, and clinical trials are currently underway. However, the most effective therapy for treating hepatic fibrosis to date is still to remove the causative agent 17 .
A number of drugs are able to reduce the accumulation of scar tissue in experimental models of chronic liver injury. Recently, NASH has been recognized as a major cause of liver fibrosis 18 . First described by Ludwig et al. it is considered part of the spectrum of nonalcoholic fatty liver disease 19 . These range from steatosis to cirrhosis and can eventually lead to hepatocellular carcinoma. NASH is a component of the metabolic syndrome, which is characterized by obesity, type II diabetes mellitus, and dyslipidemia, with insulin resistance as a common feature. As the prevalence of obesity is rapidly increasing, a rise in the prevalence of NASH is anticipated. Three systems that have been attracted much attention in liver fibrosis and portal hypertension to date includesendothelin system, sympathetic adrenergic system and the renin angiotensin system (RAS). However, the RAS blockers and agonists have been shown to be the most promising drugs, and the testing of these compounds in human liver diseases await the data generated from experimental animal models 20 .
The Rennin Angiotensin System and Hepatic Fibrosis
Authors' group has played a leading role in establishing that angiotensin (Ang) II, a key effector peptide of the renin angiotensin system (RAS), plays a central role in the pathogenesis of hepatic fibrosis and its complications [20] [21] [22] . This work has stimulated major interest in the potential therapeutic role of RAS blockade in liver disease. In addition to establishing the central role of Ang II, authorshave shown that there is an alternate, angiotensin converting enzyme 2 (ACE2) dependent arm of the RAS which is activated in both experimental and human chronic liver disease and opposes many of the vasoconstrictive and profibrotic effects of Ang II and may contribute to vasodilatation in cirrhosis [23] [24] [25] .
The demonstration that stellate cells, key effectors of hepatic fibrosis, contract, proliferate, and produce profibrotic cytokines and collagen I in response to Ang II suggested that this peptide stimulates fibrogenesis via its direct effect on these cells 17, 26 . Studies using RAS inhibitors showed that the RAS plays a major role in the pathogenesis of hepatic fibrosis 21 . These findings are now supported by a range of subsequent studies which have shown that angiotensin converting enzyme (ACE) inhibitors and Ang II type 1 receptor (AT1) blockers attenuate liver fibrosis and down-regulate key inflammatory and profibrotic cytokines 20 .
The ACE2/Ang-(1-7)/Mas Axis in Chronic Liver Disease
The classical view of the RAS is of a linear cascade in which ACE is a key enzyme, converting Ang I to the potent vasoconstrictor and profibrotic cytokine Ang II, which acts via the AT1 receptor. It is now known that there is alternate arm of the RAS in which ACE2, a homologue of ACE, degrades Ang II and generates Ang-(1-7), which in contrast to Ang II, has vasodilatory, anti-growth and anti-proliferative actions 25, 27, 28 . These effects are mediated in part by the Mas receptor, a G protein-coupled receptor (GPCR). This ACE2/Ang-(1-7)/Mas axis is thought to intrinsically regulate the RAS system by reducing Ang II levels and producing Ang- (1-7) , thus counterbalancing the potentially harmful effects of Ang II (Figure 1 ). Infusion of Ang-(1-7) into cirrhotic rats ameliorates fibrosis induced by bile duct ligation 26, 29 .
Herbal Treatments for Liver Fibrosis
Herbal medicines have been used in the treatment of liver diseases for a long time in different part of the world including China [30] [31] [32] [33] [34] [35] [36] , India 37 Iran 38 , Japan 39, 40 Mexico 41 , Sri Lanka 3-5 and several other countries. Diagnosis and treatment of liver fibrosis with integrative Chinese Medicine is well established. Several reports have demonstrated a prophylactic and therapeutic role of Chinese Medicine herbal formulas on liver fibrosis. "BJ-JN" is a traditional Chinese formulation and has an anti-oxidant activity and inhibitory activity on the activation of hepatic stellate cells (HSCs) in rats with hepatic fibrosis induced by CCl 4 , and a significant reduction in the proliferation of HSCs in vitro, leading to a significant reduction in collagen secretion 30 .
The regulation of 'redox' state within the tissue by "Yinchenhao Decoction" and "Huangqi Decoction" has been suggested as a potential mechanism by which they counter hepatic fibrosis in rats 32 . Thus, whilst "Yinchenhao Decoction" is responsible for elimination of hepatic lipid peroxide levels, "Huangqi Decoction" appears to enhance anti-oxidative ability of the tissue 32 . Moreover, "Yi Guan Jian" acts against heptocyte apoptosis and HSC activation, resulting in a diminished hepatic fibrosis 36 . The "TCM 319" is also a Chinese Medicine formula consisting f six Chinese herb extracts attenuated hepatic fibrosis induced by CCl 4 in rats 35 . The anti-fibrotic effect of TCM 319 recipe has been shown to be associated with down-regulation of gene expression of tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), platelet derived growth factor (PDGF-B) and PDGF-Rbeta, which were accompanied by reduced protein expression of PDGF-Rbeta and transforming growth factor-beta 1 (TGF-beta1) 35 .
Treatment with "BushenRougan Recipe" (BSRGR), another traditional Chinese herbal medicine, decreases the expression of collagen type I and connective tissue growth factor (CTGF) mRNAs in rats with hepatic fibrosis 33 . (Furthermore, "Dan-shao-hua-xian" capsules, preparations of traditional Chinese medicine enhance the expression of PPAR-gamma but decrease that of TNF-alpha and NF-kappaB in the fibrotic liver of rats induced by CCl 4 adminsitration 31 . Furthermore "Danshensu", "Baicalin", "Astragalus" and "Panaxnotoginsengsaponins (PNS)" four other Chinese herb products have been shown to ameliorate hepatic fibrosis in rats by mechanisms that exert inhibitory action on activation and proliferation of HSCs, and on the expression of type I and type III collagen by HSCs 34 . Collectively, these findings suggest that Chinese herbal preparations can block the progression of hepatic fibrosis and have both prophylactic and therapeutic potential in the treatment of cirrhosis.
The protective effect of "Liv-52" an Iranian herbal preparation on liver cirrhosis has been reported 38 . These protective effects were associated with anti-inflammatory, anti-oxidative and immunomodulating properties of the components in the herbal preparation 38 . It has also been reported that methanol extract of aerial parts of Leucophyllum frutescensa, a Mexican plant, is hepatoprotective 41 . The observations by Chinese, Iranian and Mexican investigators are supported by a Japanese study in which a traditional Japanese medicines "Hochu-ekki-to" and "Ninjin-youei-to" have been demonstrated to be effective as anti-fibrotic agents, and may exert their action by inhibiting pro-fibrotic cytokine production, resulting in the suppression of collagen synthesis and secretion into extracellular matric in the liver 39 . In support of these findings there are several indigenous Sri Lankan herbal preparations that are available for the treatment of end stage cirrhosis [3] [4] [5] . Few such recipes are given in Appendix A. Drugs currently available are only to manage patients suffering from liver cirrhosis and its complications such as variceal bleeding associated with portal hypertension. In Western medicine the lack of treatments to target the arrest or reverse the progression of disease hampered the clinicians to successfully treat these patients with established cirrhosis. At present, the use of herbal medicines for prevention and treatment of chronic liver diseases is in the focus of attention for both the physicians and the patients; the reasons for such shift towards the use of herbals include a considerable cost of conventional drugs, adverse drug reactions, and their inefficacy 38 . A successfully treated case of severe acute hepatitis with severe liver dysfunction in a 45-year-old well-nourished, healthy man with "Inchinko", a Chinese herbal medicine has been described and its hepatoprotective and choleretic effects were identified 40 . These therapies include several stages of treatment depending on the condition of the patient [3] [4] [5] . Therefore, extensive research should be carried out to investigate the therapeutic efficacy of indigenous herbal recipes in progressive liver fibrosis.
Conclusions
Identification of the active ingredients of herbal recipes will help to develop therapeutic strategies to arrest the progression of liver injury into liver cirrhosis. A reduction in fibrosis will be expected to improve portal hypertension, a life threatening complication of cirrhosis and thus, they can be efficiently utilized to reduce the death rate due to the end-stage liver cirrhosis and portal hypertension.
